Design of P1′ and P3′ residues of trivalent thrombin inhibitors and their crystal structures

被引:13
|
作者
Sion-Usakiewicz, JJ [1 ]
Sivaraman, J [1 ]
Li, YG [1 ]
Cygler, M [1 ]
Konishi, Y [1 ]
机构
[1] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada
关键词
D O I
10.1021/bi992419b
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthetic bivalent thrombin inhibitors comprise an active site blocking segment, a fibrinogen recognition exosite blocking segment, and a linker connecting these segments. Possible nonpolar interactions of the P1' and P3' residues of the linker with thrombin S1' and S3' subsites, respectively, were identified using the "Methyl Scan" method [Slon-Usakiewicz et al. (1997) Biochemistry 36, 13494-13502]. A series of inhibitors (4-tert-butylbenzenesulfonyl)-Arg-(D-pipecolic acid)-Xaa-Gly-Yaa-Gly-beta Ala-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(beta-cyclohexylalanine in which nonpolar P1' residue Xaa or P3' residue Yaa was incorporated, were designed and improved the affinity to thrombin. Substitution of the P3' residue with D-phenylglycine or D-Phe improved the K-i value to (9.5 +/- 0.6) x 10(-14) or 1.3 +/- 0.5 x 10(-13) M, respectively, compared to that of a reference inhibitor with Gly residues at Xaa and Yaa residues (K-i = (2.4 +/- 0.5) x 10(-11) M). Similarly, substitution of the P1' residue with L-norleucine or L-beta-(2-thienyl)alanine lowered the K-i values to (8.2 +/- 0.6) x 10-14 or(5.1 +/- 0.4) x 10(-14) M, respectively. The linker Gly-Gly-Gly-beta Ala of the inhibitors in the previous sentence was simplified with 12-aminododecanoic acid, resulting in further improvment of the K-i values to (3.8 +/- 0.6) x 10(-14) or (1.7 +/- 0.4) x 10(-14) M, respectively. These K-i values are equivalent to that of natural hirudin (2.2 x 10(-14) M), yet the size of the synthetic inhibitors (2 kD) is only one-third that of hirudin (7 kD). Two inhibitors, with L-norleucine or L-beta-(2-thienyl)alanine at the P1' residue and the improved linker of 12-aminododecanoic acid, were crystallized in complex with human alpha-thrombin. The crystal structures of these complexes were solved and refined to 2.1 Angstrom resolution. The Lys(60F) Side chain of thrombin moved significantly and formed a large nonpolar S1' subsite to accommodate the bulky P1' residue.
引用
收藏
页码:2384 / 2391
页数:8
相关论文
共 50 条
  • [21] Phenolic P2/P3 core motif as thrombin inhibitors -: Design, synthesis, and X-ray co-crystal structure
    Hanessian, S
    Therrien, E
    van Otterlo, WAL
    Bayrakdarian, M
    Nilsson, I
    Fjellström, O
    Xue, YF
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (04) : 1032 - 1036
  • [22] Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein
    Chen, VC
    Chao, L
    Chao, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) : 38457 - 38466
  • [23] Potent and selective bicyclic lactam inhibitors of thrombin:: Part 3:: P1′ modifications
    Plummer, JS
    Berryman, KA
    Cai, CM
    Cody, WL
    DiMaio, J
    Doherty, AM
    Eaton, S
    Edmunds, JJ
    Holland, DR
    Lafleur, D
    Levesque, S
    Narasimhan, LS
    Rubin, JR
    Rapundalo, T
    Siddiqui, MA
    Susser, A
    St-Denis, Y
    Winocour, P
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (06) : 835 - 840
  • [24] P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position
    Isaacs, Richard C. A.
    Newton, Christina L.
    Cutrona, Kellie J.
    Mercer, Swati P.
    Dorsey, Bruce D.
    McDonough, Colleen M.
    Cook, Jacquelynn J.
    Krueger, Julie A.
    Lewis, S. Dale
    Lucas, Bobby J.
    Lyle, Elizabeth A.
    Lynch, Joseph J.
    Miller-Stein, Cynthia
    Michener, Maria T.
    Wallace, Audrey A.
    White, Rebecca B.
    Wong, Bradley K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1532 - 1535
  • [25] Bound structures of novel P3-P1′ β-strand mimetic inhibitors of thrombin
    St Charles, R
    Matthews, JH
    Zhang, EL
    Tulinsky, A
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (08) : 1376 - 1383
  • [26] Superconvergent P1 honeycomb virtual elements and lifted P3 solutions
    Lin, Yanping
    Xu, Xuejun
    Zhang, Shangyou
    CALCOLO, 2024, 61 (04)
  • [27] The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore
    Ambler, J
    Bentley, D
    Brown, L
    Dunnet, K
    Farr, D
    Janus, D
    Le Grand, D
    Menear, K
    Mercer, M
    Talbot, M
    Tweed, M
    Wathey, B
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (08) : 1103 - 1108
  • [28] P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl α-ketoamide based HCV protease inhibitors
    Victor, F
    Lamar, J
    Snyder, N
    Yip, Y
    Guo, DQ
    Yumibe, N
    Johnson, RB
    Wang, QM
    Glass, JI
    Chen, SH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) : 257 - 261
  • [29] Potent bicyclic lactam inhibitors of thrombin:: Part I:: P3 modifications
    St-Denis, Y
    Augelli-Szafran, CE
    Bachand, B
    Berryman, KA
    DiMaio, J
    Doherty, AM
    Edmunds, JJ
    Leblond, L
    Lévesque, S
    Narasimhan, LS
    Penvose-Yi, JR
    Rubin, JR
    Tarazi, M
    Winocour, PD
    Siddiqui, MA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) : 3193 - 3198
  • [30] P1/P1′-modified benzothiadiazepines as metalloproteinase inhibitors.
    Cherney, RJ
    Maeyer, DT
    Wang, L
    Duan, JJW
    Chen, LH
    Arner, EC
    Jaffe, BD
    Covington, MB
    Decicco, CP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U940 - U940